{"id":"NCT00770874","sponsor":"Taiho Pharmaceutical Co., Ltd.","briefTitle":"Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer","officialTitle":"Phase III Study of S-1 + Cisplatin Compared With Single-agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2015-12","completion":"2016-04","firstPosted":"2008-10-10","resultsPosted":"2019-06-21","lastUpdate":"2019-06-21"},"enrollment":375,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cervical Cancer"],"interventions":[{"type":"DRUG","name":"S-1 + Cisplatin (arm A)","otherNames":[]},{"type":"DRUG","name":"Cisplatin (arm B)","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"This study is an open-label, multicenter, multinational, two-arm, parallel randomized Phase 3 study evaluating the efficacy and safety of S-1+Cisplatin versus single-agent Cisplatin in patients with stage IVB, recurrent or persistent carcinoma of the cervix.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From the date of randomization to death from any cause, assessed up to 296 events or the end of November 2015, whichever was earlier, each three months","effectByArm":[{"arm":"S-1 + Cisplatin (Arm A)","deltaMin":21.9,"sd":null},{"arm":"Cisplatin (Arm B)","deltaMin":19.5,"sd":null}],"pValues":[{"comp":"OG000","p":"0.125"}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":4,"countries":["Japan","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":188},"commonTop":["Nausea","Decreased appetite","Haemoglobin decreased","Neutrophil count decreased","Fatigue"]}}